Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Clinical utility of varenicline for smokers with medical and psychiatric comorbidity

Authors Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, et al

Published Date November 2009 Volume 2009:4 Pages 421—430

DOI http://dx.doi.org/10.2147/COPD.S6300

Published 17 November 2009

Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, Michael V Burke, JT Hays

Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA

Abstract: Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.

Keywords: smoking cessation, chronic obstructive pulmonary disease, varenicline

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Varenicline for smoking cessation: efficacy, safety, and treatment recommendations

Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, et al

Patient Preference and Adherence 2010, 4:355-362

Published Date: 13 September 2010

Readers of this article also read:

MRI-detectable polymeric micelles incorporating platinum anticancer drugs enhance survival in an advanced hepatocellular carcinoma model

Vinh NQ, Naka S, Cabral H, Murayama H, Kaida S, Kataoka K, Morikawa S, Tani T

International Journal of Nanomedicine 2015, 10:4137-4147

Published Date: 25 June 2015

Validity and reliability of the Turkish version of CRAFFT Substance Abuse Screening Test among adolescents

Kandemir H, Aydemir Ö, Ekinci S, Selek S, Kandemir SB, Bayazit H

Neuropsychiatric Disease and Treatment 2015, 11:1505-1509

Published Date: 22 June 2015

Nanofabrication of methylglyoxal with chitosan biopolymer: a potential tool for enhancement of its anticancer effect

Pal A, Talukdar D, Roy A, Ray S, Mallick A, Mandal C, Ray M

International Journal of Nanomedicine 2015, 10:3499-3518

Published Date: 12 May 2015

Water-soluble l-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma

Liang SY, Zhou Q, Wang M, Zhu YH, Wu QZ, Yang XL

International Journal of Nanomedicine 2015, 10:2325-2333

Published Date: 23 March 2015

Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma

Ochi N, Goto D, Yamane H, Yamagishi T, Honda Y, Monobe Y, Kawamoto H, Takigawa N

OncoTargets and Therapy 2014, 7:1847-1850

Published Date: 7 October 2014

Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer

Sun W, Ai T, Gao Y, Zhang Y, Cui J, Song L

OncoTargets and Therapy 2013, 6:1315-1323

Published Date: 18 September 2013

Cognitive function affects trainability for physical performance in exercise intervention among older adults with mild cognitive impairment

Uemura K, Shimada H, Makizako H, Doi T, Yoshida D, Tsutsumimoto K, Anan Y, Suzuki T

Clinical Interventions in Aging 2013, 8:97-102

Published Date: 30 January 2013

Treatment of COPD: A matrix perspective

Sarah E Dunsmore

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:113-122

Published Date: 18 March 2008